Kairos Pharma, Ltd.
KAPA
$0.9074
-$0.077-7.82%
AMEX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 132.08% | 30.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 72.52% | -22.65% | |||
| Operating Income | -72.52% | 22.65% | |||
| Income Before Tax | -313.83% | 21.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -313.83% | 21.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -313.83% | 21.67% | |||
| EBIT | -72.52% | 22.65% | |||
| EBITDA | -88.46% | 26.32% | |||
| EPS Basic | -300.00% | 21.57% | |||
| Normalized Basic EPS | -300.00% | 21.47% | |||
| EPS Diluted | -300.00% | 21.57% | |||
| Normalized Diluted EPS | -300.00% | 21.47% | |||
| Average Basic Shares Outstanding | 3.29% | 0.00% | |||
| Average Diluted Shares Outstanding | 3.29% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||